Expertise in
10
conditions

Antonia Sampol

Palma, PM, ES 
Expertise in
10
conditions
Palma, PM, ES 
OverviewLocationsClinical Research

Overview

Antonia Sampol practices in Palma, Spain. Ms. Sampol is highly rated in 10 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Multiple Myeloma, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 73 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Palma, PM, Spain
Other Locations
Porto Do Son, GA, Spain
Islabekoa, PV, Spain
Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
A Phase 3, Multicenter, Open-label, Randomized, Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes With Excess Blasts-2 (MDS-EB2) With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML / AMLSG 28-18)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin
Study Phase: Phase 3
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim
Study Phase: Phase 3
View 1 Less Clinical Trial

73 Total Publications

Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection.
Multiclonal Profiling of FLT3-ITD in AML Using MinION Sequencing: A Tailored Clustering Approach to Enhance Subclonal Detection.
Journal: OncoTargets and therapy
Published: April 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Sampol's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile